Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Chickenpox Vaccine Market Expected to Grow Between 2025 And 2029?

The market for the chickenpox vaccine has been on a robust growth trajectory in the past years. It promises to surge from a value of $3.57 billion in 2024 to $3.76 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.5%. Factors such as the advancement in vaccine research, regulatory green signals, rate of occurrence of the disease, policies regarding vaccination, and initiatives related to public health have been instrumental in spurring the growth during the previous period.

The market of chickenpox vaccine is anticipated to witness significant expansion in the coming years. The market is predicted to reach $4.82 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%. Various factors can be credited for this anticipated growth during the forecast period like public faith and understanding, readiness for pandemics, research activities and advancements, rising requirement in emerging markets, and development of healthcare infrastructure. The forecast period is also expected to see certain trends such as educational drives for vaccines, monitoring of adverse events, strategies related to vaccine pricing, breakthrough innovations, and the implementation of AI.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

What Are the Core Growth Drivers Propelling the Chickenpox Vaccine Market Forward?

The growth of the chickenpox vaccine market is likely to receive significant momentum due to the increasing cases of chickenpox disease. Chickenpox is a severe infectious disease caused by the varicella-zoster virus (VZV), which results in a fluid-filled rash accompanied by itching. The surge in chickenpox cases necessitates an increase in varicella vaccine immunization, thereby enhancing the demand for chickenpox vaccines. For example, the National Library of Medicine (NLM), a renowned US-based biomedical library, published a report in October 2023 stating that a study conducted from September 2016 to December 2022 revealed the average weekly rate of 3.4 GP consultations per 100,000 people in England for chickenpox during weeks 13 to 15 each year. During the COVID-19 pandemic, these typical epidemic peaks were absent due to lockdowns and social distancing measures. Despite this, the consultation rate among children under one year old was higher in 2022 than in the pre-pandemic years, pointing to altered transmission patterns. These factors collectively contribute to the escalating prevalence of chickenpox disease, fuelling the growth of the chickenpox vaccine market.

What Segment Types Define the Chickenpox Vaccine Market Structure?

The chickenpox vaccine market covered in this report is segmented –

1) By Vaccine: Monovalent Varicella Vaccine, Combination Varicella Vaccine

2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination

3) By End-Users: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine

2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, And Varicella (MMRV) Vaccine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8581&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Chickenpox Vaccine Market?

North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theChickenpox Vaccine Industry Evolution?

The chickenpox vaccine market is witnessing a significant trend of innovative drug advancements. Established companies in the industry are creating groundbreaking medications featuring greater effectiveness and unique derivatives to maintain market dominance. In November 2022, Sinovac Biotech Ltd., a company from China that specializes in vaccine research, manufacturing, and development, announced that its live attenuated chickenpox (varicella) vaccine had received prequalification from the World Health Organization (WHO); being the first varicella vaccine to receive such recognition globally. The varicella vaccine is derived from the Oka strain and is manufactured in the unique Human Diploid Cell (SV-1 strain) of SINOVAC, which is created by cultivating and harvesting the virus, adding stabilizers, and then freeze-drying it. A phase III efficacy trial, involving a group of children aged 1 to 12, demonstrated a 97.1% seroconversion rate. Additionally, the vaccine showed an 87.1% and 89.2% effectiveness against varicella and breakthrough varicella, respectively. The vaccine also provided 100 percent protection against both mild and severe conditions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

What Is the Definition of the Chickenpox Vaccine Market?

Chickenpox vaccines are biological preparations that stimulate the cell-mediated immune response and prepare it to fight future infections caused by viruses by triggering IgG-mediated production of antibodies against varicella-zoster-specific pathogens that enter the body. The varicella-zoster virus causes chickenpox, which is a highly contagious disease (VZV).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8581

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model